

Global HCV Treatment Expansion: A Gilead Sciences Update

July 2015



Access to Gilead HCV Medicines in U.S. and Europe

Broad Access in the U.S.

- 210,000 patients treated in the U.S. through Q1 2015
- Wide formulary adoption – significant discounts with many providers
- Positive treatment guidelines / cost-effective reports
 - ✓ American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) analysis
 - ✓ Recommendations for Sovaldi/Harvoni in AASLD guidelines
 - ✓ Increased use of 8 week regimen
 - ✓ Real world data supporting clinical trial data

Ongoing Positive Reimbursement in Europe

- 50,000 patients treated in Europe through Q1 2015
- HTA recommendations, e.g. NICE
- Governments committing to volume-based agreements to expand access

Access to Gilead HCV Medicines in Developing Countries

Registrations

- Commitment to register in all countries, seeking clinical trials waivers to speed up access
 - ✓ Approvals in 13 low/middle-income countries to date, including Brazil, India, Georgia, Pakistan, Egypt and Mongolia
 - ✓ Currently planning GS-5816 registration strategy

Relevant Data

- Clinical trials across broad patient populations including in-country trials - e.g. China, India, Vietnam
 - ✓ Key demonstration projects, e.g. Rwanda Partners in Health study, Georgia eradication program with Ministry of Health

Pricing

- Flat public/government pricing structure for all low-income and nearly all low-middle income countries (300USD Sovaldi / 400USD Harvoni)
- Pre-FDA approval, agreed licensing program (SOF, LDV/SOF, SOF/GS-5816) with 11 Indian generic drug manufacturers
 - ✓ 91 countries (including more than 54 MICS), home to 100+ million patients
 - ✓ Local manufacturing agreements in place in Egypt and Pakistan
- Anti-diversion measures allow simplified procurement, no patient info/citizenship

Examples: Access to Sovaldi/Harvoni

Georgia

HCV drug donation and grant program with MoH and CDC; goal to treat 5,000 patients first year, scaling to **20,000** per year

Mongolia

Sovaldi & Harvoni approved; working with MoH on HCV education programs

India

Eight licensed generic products launched

Pakistan

Sovaldi approval and more than **15,000** patients treated to date

Egypt

National HCV treatment program; **95,000** patients treated to date

Brazil

Government committing to treating **60,000** patients over next 2 years

